Yahoo Finance

Goldman Sachs upgraded Autolus Therapeutics (AUTL) to Buy from Neutral with a price target of $7.60, up from $7. The recent approval of lead asset Aucatzyl represents a de-risking event for the company’s technology platform and manufacturing facilities and the label granted by the FDA supports Aucatzyl’s differentiated safety profile, contends the firm, which sees “a significant dislocation between the company’s fundamental valuation and current market value.”

Don't Miss our Black Friday Offers:

• Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks

• Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on AUTL:

• Autolus Therapeutics upgraded to Buy from Neutral at Redburn Atlantic

• Autolus Therapeutics Q3 2024 Financial Update and FDA Approval

• Autolus Therapeutics Wins FDA Approval for AUCATZYL®

• Autolus Therapeutics Gains FDA Approval for AUCATZYL®

• Autolus Therapeutics reports Q3 EPS (31c), consensus (21c)